Trigger Lock

Micropump for Narcotic/Opioid Analgesics Abuse Resistance

Opioid analgesics are used to treat patient suffering from severe and chronic pain. The market for opioid drugs in the seven major markets (USA, Japan, and 5 European countries) was estimated to exceed $7.4 billion in 2010, dominated by oxycodone molecule. It is forecasted to reach $7.9 billion by 2012.

A major problem faced by the industry is the growing abuse and misuse of its controlled-release drugs by drug abusers, who extract the opioids from the drugs and achieve their immediate release. The proportion of narcotic/opioid analgesics abuse associated with emergency room admissions has more than tripled, from 6.8% in 1998 to 26.5% in 2008. Narcotic/opioid analgesics abuse continues to increase as current products remain easy to abuse.

Trigger Lock successfully addresses the issue of narcotic/opioid analgesics tampering:

  • Micropump particles cannot be crushed to extract the narcotic/opioid analgesics;
  • Prevent misuse of scheduled drugs such as narcotic/opioid analgesics;
  • Additional modifications tailored to prevent other less publicized methods of foiling controlled release systems;
  • Provides either bioequivalent or improved pharmacokinetics to marketed narcotic/opioid analgesics; and,
  • May be applied to novel, already-marketed, or off-patent narcotic/opioids.

FDA plans to implement a Risk Evaluation and Mitigation Strategy (REMS) requirement for all extended-release opioid analgesics. The FDA’s move to restrict prescribing extended-release opioid analgesics should benefit tamper-resistant formulations such as Trigger Lock-based formulations of opioids.